The American Red Cross (ARC), also known as the American National Red Cross, is a humanitarian organization that provides emergency assistance, disaster relief, and education inside the United States. It is the designated U.S. affiliate of the International Federation of Red Cross and Red Crescent Societies. It is the largest single supplier of blood and blood products in the United States, collecting and processing approximately 40 percent of the blood supply and distributing it to about 2,600 hospitals and transfusion centers nationwide. The organization researches and tests to protect the safety of the blood supply. It was among the first to develop and implement testing for many infectious diseases including, HIV, hepatitis B and C viruses, West Nile virus, and Chagas disease. The ARC operates the nationwide hemovigilance program to examine donor and patient adverse reactions. Data from the program is used to enhance blood product quality and safety The ARC serves on key committees of AABB and other blood-related organizations, and works closely with the U.S. Food and Drug Administration (FDA). The American Red Cross was established in 1881 and is headquartered in Washington, District of Columbia with 39 immunohematology reference laboratories nationwide.

Virginia Tech Intellectual Properties, Inc. handles, protects and licenses technologies developed by the faculty, staff and students. It facilitates the licensing of technology to companies, encourages new faculty startup ventures, works with publishers and distributors of software, and supports the transfer of research and knowledge to other universities, research institutes and companies. The company was founded in 1985 and is headquartered in Blacksburg, VA.

Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA.

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X.

Cyclogenix is a UK-based biotech focused on the development of novel biotherapeutics with wide-ranging expertise in cyclotide-based drug delivery systems and antibody engineering. Having successfully attracted funding from large Pharmaceutical companies, venture groups and public agencies, our main interests for research and development currently are: Human Antibody Engineering VNAR Antibody Agents Cyclic Peptide Applications Biotherapeutic Delivery & Disease Targeting

Wuxi Kejienuo Biotechnology Co., Ltd., established on 2010-12-30, The business scope includes R&D and technical services of animal bioreactor technology and products;food,food additives,Healthy food,medicine,R&D of cosmetics.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shandong Chentai Pharmaceutical Co., Ltd., established on 2018-04-23, Business scope includes research and development and sales of biomedicine,Technical Services,Technology Promotion;drug additives,Research and development of agricultural technology,Sales and technical promotion services;biopharmaceuticals,Pharmaceutical Intermediates,Veterinary Drug Intermediates,R&D and sales of pesticide intermediates and raw materials;medical products,Chemical Products,Chemical raw materials,Chemical Reagent(None of the above contain hazardous chemicals)promotion of;Fertilizer retail;General cargo import and export business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

iMFLUX, Inc., part of Procter & Gamble Co., is an American company located in Hamilton, OH, that operates as software and engineering company. Mary Kostolansky Wagner has been the CEO of the firm since 2019.\nThe company says this about itself: iMFLUX (a wholly owned subsidiary of Procter & Gamble) is a software and engineering innovation company that partners with leaders in the plastics industry, injection molding machine manufacturers, injection molding customers and resin suppliers, delivering significant, sustainable competitive advantage in their market segments. iMFLUX’s core technical competencies include polymer processing, machine control software and hardware, mold design and fabrication, materials expertise, metrology & analytics and industrial design. This unique combination of technical expertise all under one roof provides our customers with a one-stop solution to some of the most challenging engineering challenges the industry faces.

Beijing Jifulin Biotechnology Co., Ltd., established on 2009-12-25, Business scope includes technology development,technology transfer,technical consulting,Technical Services,Technology Promotion;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Agricultural Science Research and Experimental Development;Medical Research and Experimental Development;sell cosmetics,fertilizer.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

SK Discovery helps each operating company achieve Biz. They establish and actively implement new growth strategies suitable for each company's characteristics and constantly strive to create customer value that fits. This is a chemical manufacturer and distributor company.

Agriculture Victoria Services is a non-profit organization that provides agricultural policy development and compliance services.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.